David M. Nanus, MD, chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discusses the use of immunotherapy in the community setting. He also gives advice to community oncologists that are using these treatments in their practice. <br />
David M. Nanus, MD, chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discusses the use of immunotherapy in the community setting. He also gives advice to community oncologists that are using these treatments in their practice.
Community oncologists are using immunotherapies to treat patients with many common cancer types, Nanus says. However, these treatments can have a variety of side effects with which not all doctors are familiar.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More